Overview

Country(s): Austria, Belgium, Canada, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey,

Deadline: 18-02-2020 Pre-proposals

Deadline:16-06-2020 Invited full proposals

PROGRAMME SUMMARY

The ERA-Net E-Rare has successfully implemented ten Joint Transnational Calls for rare disease research projects since 2006. This effort continues in the framework of the European Joint Programme on Rare Diseases (EJP RD) that has been established to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC).

2020 topic

‘Pre-clinical research to develop effective therapies for rare diseases’

Visit EJP RD website

View full text on EJP RD website

FUNDING SPECIFICS

The FNR supports Luxembourg partners in this Call with a maximum of 300,000 EUR.

APPLICATION INFORMATION

Submission

Both pre- and full proposals must be written in English and must be submitted to the Joint Call Secretariat (JCS) by the coordinator through the electronic submission system exclusively. Specific information to follow.

In addition, Luxembourg partners must submit both pre and full proposals, along with the FNR INTER Call documents to the FNR no later than 5 working days after the EJP-RD deadline. Applications to the FNR must be submitted via the FNR’s Online Grant Management System.

Call timeline

There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals.

  • Pre-proposal submission deadline: 18 February 2020.
  • Invitation to full proposal: end April 2020.
  • Full proposal submission deadline: 16 June 2020.
  • Deadline for rebuttals: 28 July 2020.
  • Notification of funding decision: November 2020.
This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement